1 REIMAGINE 2 was a 68-week phase 3 trial evaluating the safety and efficacy of CagriSema in doses 2.4 mg/2.4 mg and 1 mg/1 mg once weekly versus semaglutide 2.4 mg, semaglutide 1 mg, cagrilintide 2.4 mg, and dose-matched placebo in 2,713 adults with T2D inadequately controlled with metformin with or without an SGLT2 inhibitor
If your compound includes B12, the dosing charts in this guide still apply for the tirzepatide component, as the B12 addition does not change the tirzepatide concentration calculations
The gradual progression serves pharmacodynamic purposes beyond simple tolerability, allowing metabolic adaptations to develop fully
10.25011/cim.v37i3.21379 104 XuC.SunL.RenF.HuangP.TianZ.CuiJ.et al (2020)
Multiple assays were performed to assess cellular status and molecular changes
(3)Fmoc-Gly-Leu-Val-WangResin (3) Preparation of Fmoc-Gly-Leu-Val-WangResin (2)Fmoc-Leu-Val-WangResin(20DMF)5203DMF3DMF2Fmoc-Gly-OH0.7gDIEA0.4mlTBTU0.56gHOBT0.2gDMF10ml1.53DMF3DMF2Fmoc-Gly-Leu-Val-WangResin In the Fmoc-Leu-Val-WangResin of step (2), add decapping reagent (DMF solution of 20% piperidine), react at room temperature for 5 minutes, drain, add decapping reagent at room temperature and react for 20 minutes, wash with isopropanol 3 times, washed 3 times with DMF, washed 2 times with re-distilled DMF, drained, added Fmoc-Gly-OH0.7g, DIEA0.4ml, TBTU0.56g, HOBT0.2g, DMF10ml, reacted at room temperature for 1.5 hours, pumped with a vacuum pump Dry, wash 3 times with isopropanol, wash 3 times with DMF, wash 2 times with DMF that has been distilled, and drain to obtain Fmoc-Gly-Leu-Val-WangResin
